Jetema: Supply contract signed
AI reading
★★★★ Bullish · Contract win
Signs exclusive supply deal for botulinum toxin drug
Key figures: ₩30.15bn contract, 39.66% of revenue
An AI model read the opening section of the filing and rated it relative to the company's size. It can be wrong, so check the original filing on DART (Korean).
Other filings by Jetema
For information only. Not investment advice.